NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View

Novavax (NVAX) reported Q2 2025 EPS of $0.62 and revenues of $239 million, both surpassing consensus estimates, with the revenue beat largely driven by a $175 million milestone payment from Sanofi. The company raised its 2025 adjusted revenue forecast to $1B-$1.05B, primarily due to Sanofi cost reimbursements and the completed transition of Nuvaxovid's global commercial leadership to Sanofi for the 2025-2026 season. This strategic shift, which is expected to reduce Novavax's operating expenses and leverage Sanofi's extensive distribution network, drove a nearly 13% increase in NVAX shares.

Analysis

Novavax (NVAX) reported second-quarter 2025 results that surpassed consensus estimates, with EPS of $0.62 and revenue of $239 million. However, this performance is heavily qualified by its composition and year-over-year declines. The revenue beat was driven almost entirely by a $175 million milestone payment from its partner Sanofi (SNY), masking a significant 42% year-over-year revenue drop and weak underlying product sales, which fell to just $11 million from $23 million in the prior-year period. The core of the investment thesis has shifted to a strategic restructuring centered on the Sanofi partnership, which now assumes global commercial leadership for the Nuvaxovid vaccine. This transition is responsible for a sharp reduction in operating expenses, with R&D and SG&A costs falling 26% and 57% respectively, and was the primary catalyst for the stock's recent 13% gain. While the company raised its 2025 adjusted revenue forecast to a range of $1 billion to $1.05 billion, this revision is attributed to a $20 million cost reimbursement from Sanofi, not an improvement in organic sales. The withholding of full-year revenue guidance highlights the company's dependence on Sanofi's sales forecasts and execution. Future growth catalysts, including the COVID-influenza combination and H5N1 vaccine candidates, remain in development and require further funding, positioning them as long-term, speculative opportunities.

Key Decisions for Investors

• Investors should recognize that Novavax's valuation is now primarily tied to the execution of its Sanofi partnership and the realization of future milestone and royalty payments, as the company's standalone commercial capabilities and direct product sales have become negligible.
• Monitor the company's cash burn rate relative to its remaining cash balance of $628 million, as continued operational funding and pipeline advancement depend heavily on the timely receipt of milestone payments from Sanofi and the potential to secure new strategic collaborations.
• Re-evaluate financial models to reflect a licensing and royalty-based revenue structure, and watch for any forward-looking statements from Sanofi regarding Nuvaxovid's market uptake, as this will be the most critical indicator of Novavax's future revenue stream.